Zobrazeno 1 - 10
of 313
pro vyhledávání: '"Douglas V Faller"'
Autor:
Michael S Boosalis, Jose I Sangerman, Gary L White, Roman F Wolf, Ling Shen, Yan Dai, Emily White, Levi H Makala, Biaoru Li, Betty S Pace, Mehdi Nouraie, Douglas V Faller, Susan P Perrine
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144660 (2015)
High-level fetal (γ) globin expression ameliorates clinical severity of the beta (β) hemoglobinopathies, and safe, orally-bioavailable γ-globin inducing agents would benefit many patients. We adapted a LCR-γ-globin promoter-GFP reporter assay to
Externí odkaz:
https://doaj.org/article/2e893cb55f4d4593925e8200028f48ee
Autor:
Nishant Kumar, Nicole J. Zhang, Dasha Cherepanov, Dorothy Romanus, Michael Hughes, Douglas V. Faller
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-10 (2022)
Abstract Background Amyloid light-chain (AL) amyloidosis is an ultra-rare disease associated with significant morbidity and mortality. Few studies have examined the global epidemiology of this condition. Methods This study estimated the diagnosed inc
Externí odkaz:
https://doaj.org/article/c47e709a06194b54b19540237909afc4
Autor:
Joshua F. Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J. Fram, Douglas V. Faller, Mehul Dalal, Lionel Ades, Mikkael A. Sekeres
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/95f7a88397bf4e219d56b908c3cff6b5
Autor:
Antoine Regnault, Farrah Pompilus, Anna Ciesluk, Flora Mazerolle, Rafael Bejar, Robert J. Fram, Douglas V. Faller, Patrick Marquis, Jill A. Bell
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-10 (2021)
Abstract Purpose Physical functioning and fatigue are key patient concerns in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The objective of this research was to generate supportive quantit
Externí odkaz:
https://doaj.org/article/de5ba6e0bd2d46d3a9a051325a0af47b
Autor:
Xiaofei Zhou, Sharon Friedlander, Erik Kupperman, Farhad Sedarati, Shingo Kuroda, Zhaowei Hua, Ying Yuan, Yuka Yamamoto, Douglas V. Faller, Kazue Haikawa, Katsuhiko Nakai, Sharon Bowen, Yi Dai, Karthik Venkatakrishnan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 1069-1081 (2021)
Abstract The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐r
Externí odkaz:
https://doaj.org/article/a8426999b0604c1f851464ce578e755b
Autor:
Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan O. Schönland, Heather J. Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Dasha Cherepanov, Vanessa C. Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis
Publikováno v:
American Journal of Hematology. 98:720-729
Autor:
Xiaofei, Zhou, Debra L, Richardson, Afshin, Dowlati, Sanjay, Goel, Solmaz, Sahebjam, James, Strauss, Sant, Chawla, Ding, Wang, Diane R, Mould, Vivek, Samnotra, Douglas V, Faller, Karthik, Venkatakrishnan, Neeraj, Gupta
Publikováno v:
Clinical Pharmacology in Drug Development. 12:257-266
The purpose of this study was to assess the effect of pevonedistat, a neural precursor cell expressed, developmentally down-regulated protein 8 (NEDD8)-activating enzyme inhibitor, on the heart rate-corrected QT (QTc) interval in cancer patients. Pat
Autor:
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Publikováno v:
Scientia
Pevonedistat; Chronic myelomonocytic leukemia Pevonedistat; Leucemia mielomonocítica crónica Pevonedistat; Leucèmia mielomonocítica crònica PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monoth
Autor:
Yan Dai, Douglas V. Faller, Alexander J. Stankiewicz, Katelyn G. Enzer, Christine Y. Chiao, Lijia Zhu
P27Kip1 (CDKN1B) regulates cellular proliferation and senescence, and p27Kip1 deficiency in cancer is strongly correlated with poor prognosis of multiple cancer types. Understanding the mechanism of p27Kip1 loss in cancer and the consequences of rest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51373b60d0be2f0fb7ea91246551165d
https://doi.org/10.1158/1541-7786.c.6540112.v1
https://doi.org/10.1158/1541-7786.c.6540112.v1
Autor:
Yan Dai, Douglas V. Faller, Alexander J. Stankiewicz, Katelyn G. Enzer, Christine Y. Chiao, Lijia Zhu
Fig.S1: The level of p27Kip1 mRNA was unaffected by SIRT1 silencing. The mRNA levels of p27 were measured by quantitative RT-PCR analysis. 5 mg RNA extracted from SIRT1 silenced (shSIRT1) or shRNA control (shControl) H1299 and H460 cells. The mRNA le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48c2efb0bae8f8a8fee88c1dd1819605
https://doi.org/10.1158/1541-7786.22512049
https://doi.org/10.1158/1541-7786.22512049